Navigation Links
AMT to Release Full Year 2008 Results on February 24, 2009
Date:2/18/2009

AMSTERDAM, The Netherlands, February 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will release its financial results for the full year 2008 on Tuesday, February 24, 2009 at 7:00 am Central European Time (CET). To discuss these results, the Company will conduct a conference call that day at 3 p.m. CET.

The dial-in number for the Netherlands is 0800-949-4166 (toll free). The number for Germany is 0800-000-22-63 (toll free). For the UK the number is +44-207-107-0611 and for the rest of Europe: +41-91-610-5600. The number for the USA is +1-866-291-4166 (toll free). To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website fifteen minutes prior to the call to register, download and install the necessary audio software.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV GMP production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of (rare) diseases that are caused by one faulty gene. AMT currently has a product pipeline with nine products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Edition of Definitive Resource in Tissue Engineering Released Today
2. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
3. Instant JChem 2.0 Released: Instant JChem Personal Free for All Users
4. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
5. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
6. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
7. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
8. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
9. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):